Payment overview · 2025
General Payments
$1,510.57
68 reported records · 20 companies
Healthcare provider profile · identity verified
Khaled A Osman, D.O
Allopathic & Osteopathic Physicians|General Practice · ASTORIA, NY · NPI 1518131846
Verified facts
What the public records show
CMS Open Payments records show Khaled A Osman, D.O received $1,510.57 in general payments during 2025 across 68 reported records.
Abbott Laboratories accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $192.41 | 12.7% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $182.13 | 12.1% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $159.50 | 10.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $146.41 | 9.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.35 | 7.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $94.35 | 6.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.31 | 5.8% | 4 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $78.36 | 5.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.28 | 4.5% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.00 | 4.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.23 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.91 | 3.2% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $47.55 | 3.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $45.67 | 3.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.64 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.13 | 1.5% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $22.72 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.66 | 1.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.81 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,510.57 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $192.41 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $182.13 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $159.50 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $146.41 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.35 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $94.35 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.98 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $87.31 | 4 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $78.36 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $78.36 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $78.36 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $66.00 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.85 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.85 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 157 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
157 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 545 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 476 | 74 |
| Simvastatin | Simvastatin | 471 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 61 |
| Metformin Hcl | Metformin Hcl | 371 | 64 |
| Losartan Potassium | Losartan Potassium | 321 | 47 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 303 | 39 |
| Omeprazole | Omeprazole | 280 | 53 |
| Lisinopril | Lisinopril | 255 | 38 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 212 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 30 |
| Famotidine | Famotidine | 197 | 45 |
| Allopurinol | Allopurinol | 176 | 30 |
| Vascepa | Icosapent Ethyl | 176 | 31 |
| Linzess | Linaclotide | 169 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 26 |
| Januvia | Sitagliptin Phosphate | 166 | 23 |
| Ozempic | Semaglutide | 161 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 31 |
| Mounjaro | Tirzepatide | 157 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 26 |
| Glimepiride | Glimepiride | 135 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 24 |
| Montelukast Sodium | Montelukast Sodium | 129 | 49 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 125 | 15 |
| Farxiga | Dapagliflozin Propanediol | 118 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 56 |
| Metformin Er Gastric | Metformin Hcl | 118 | 19 |
| Diclofenac Potassium | Diclofenac Potassium | 104 | 17 |
| Trulicity | Dulaglutide | 104 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 102 | 29 |
| Alcohol Pads | Alcohol Antiseptic Pads | 94 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 13 |
| Enalapril Maleate | Enalapril Maleate | 91 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 90 | 16 |
| Celecoxib | Celecoxib | 90 | 40 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 88 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 15 |
| Meloxicam | Meloxicam, Submicronized | 83 | 20 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 83 | 14 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 81 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 81 | 29 |
| Carvedilol | Carvedilol | 79 | 11 |
| Finasteride | Finasteride | 79 | 11 |
| Meloxicam | Meloxicam | 79 | 25 |
| Novolog Flexpen | Insulin Aspart | 75 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 74 | 16 |
| Gabapentin | Gabapentin | 73 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 73 | 22 |
| Jardiance | Empagliflozin | 70 | 14 |
| Azithromycin | Azithromycin | 69 | 45 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 62 | suppressed |
| Colchicine | Colchicine | 62 | 12 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 61 | 18 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 59 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Naproxen | Naproxen | 54 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Zileuton Er | Zileuton | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 14 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 20 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Furosemide | Furosemide | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 21 |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 37 | suppressed |
| Lidocaine | Lidocaine | 37 | 12 |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Procto-Med Hc | Hydrocortisone | 36 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 32 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 31 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 31 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 31 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Proctosol-Hc | Hydrocortisone | 27 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Prolia | Denosumab | 23 | 13 |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Aripiprazole Odt | Aripiprazole | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Permethrin | Permethrin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Corlanor | Ivabradine Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,510.57 · 68 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ENTRESTO, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, IBSRELA, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, LEQVIO, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Veozah, XIFAXAN, Xhance, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error